Good morning :)
$
₹
Celcuity LLC

Celcuity LLC

CELC

NASDAQ
Asset Logo

Celcuity LLC

CELC

NASDAQ
$68.571.64% (-1.14)
$
₹
$68.571.64% (-1.14)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $3.3B the stock is ranked 1757

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

78.90
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.31
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 13 analysts reports

Buy
13 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+127.7%

Earnings Growth

-39.08%

Rev. Growth

+13214.99%

See Detailed Forecast

Company Profile

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 127.70% growth, versus a trailing 3-year CAGR of 84.50%.

2026
Current$67.07Baseline
Analyst Target - 1 year
Target$152.72+127.7%

All values in $

202220232024202520262027$50.83$89.89$128.94Target+127.7%
2026
Current$67.07Baseline
Analyst Target - 1 year
Target$152.72+127.7%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$154Baseline
Forecast for Dec 2026
High$57,886+37488.31%
Average$20,505.08+13214.99%
Low$6,500+4120.78%

All values in $ Thousand

2021202220232024202520260000154Low+4120.78%Average+13214.99%High+37488.31%
2025
Current$154Baseline
Forecast for Dec 2026
High$57,886+37488.31%
Average$20,505.08+13214.99%
Low$6,500+4120.78%

All values in $ Thousand

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-3.25Baseline
Forecast for Dec 2026
High$-4.3-32.31%
Average$-4.52-39.08%
Low$-4.74-45.85%

All values in $

202120222023202420252026-1.59-2.52-2.44-2.62-3.25Low-45.85%Average-39.08%High-32.31%
2025
Current$-3.25Baseline
Forecast for Dec 2026
High$-4.3-32.31%
Average$-4.52-39.08%
Low$-4.74-45.85%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0.1
-43.8
-50.9
-52.8
-78.8
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000.12000.15000
Net Income-21.61-23.72-29.79-36.65-36.99-45.26-43.80-50.97-52.84-78.86
Net Profit Margin----30205.89%---28444.15%---
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Celcuity LLC -78.90-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CELC with any stock or ETF
Compare CELC with any stock or ETF
Comparing from
CELC
ABBV
AMGN
Loading...

Frequently asked questions

  1. Celcuity LLC (CELC) share price today is $68.57 as of November 5, 2026 at 1:18 AM IST. The stock touched a day high of $72.17 and a day low of $67.58.

  2. Celcuity LLC stock trades on NASDAQ under the ticker symbol CELC.

  3. Celcuity LLC's market capitalization is $3.28B as of November 5, 2026 at 1:18 AM IST.

  4. Celcuity LLC's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Celcuity LLC's price-to-book (P/B) ratio is 78.90 as of November 4, 2026.

  6. Yes, You can buy Celcuity LLC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Celcuity LLC shares in three steps: 1. Search Celcuity LLC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Celcuity LLC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Celcuity LLC (CELC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1458 shares at the current price of $68.57.

Loading...